Xencor, Inc.

Biopharmaceutical companies celebrated recent positive data readouts with a slew of significant follow-on public offerings (FOPOs), including Nuvalent, Inc. , which grossed $500m on 16 September from

Who: Xencor/Janssen Biotech What: The Johnson & Johnson subsidiary is returning worldwide rights to plamotamab, a CD20xCD3 bispecific T-cell engager, to Xencor less than three years after licensing

Zenas BioPharma is ahead of the pack compared with most companies advancing CD19-targeting therapeutics for autoimmune diseases, with plans to report Phase III results in IgG4-related disease and Pha

Who: Merck KGaA/Caris Life Sciences What: Caris’s research division will discover novel targets for use in cancer antibody-drug conjugate products to be developed by Germany’s Merck. Why: Merck K